Patent 9718893 was granted and assigned to SYNIMMUNE GmbH on August, 2017 by the United States Patent and Trademark Office.
The present invention relates to a bispecific antibody molecule, as well as a method for producing the same, its use and a nucleic acid molecule encoding the bispecific antibody molecule. The invention in particular provides an antibody molecule that is capable of mediating target cell restricted activation of immune cells.